EN | SE Contact us Careers


BioInvent’s partnering strategy is based on:

  • Out-licensing opportunities with partners that can further develop and commercialize BioInvent’s proprietary pipeline assets.
  • Research and development partnerships based on F.I.R.S.T™ and n-CoDeR®.
  • Production of antibodies to external parties.

BioInvent has several licensing agreements and research collaborations with leading pharmaceutical companies:


  • Exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in mainland China, Taiwan, Hong Kong and Macau.
  • In December 2020, Pfizer selected antibodies directed at a previously-selected target under the cancer immunotherapy research collaboration.
  • BioInvent is eligible for potential future development milestones in excess of USD 100 million if an antibody is developed through to commercialization, as well as up to double digit royalties.
  • Co-developing (50/50 split of costs and profits) of oncolytic virus candidates for solid tumors, leveraging BioInvent’s n-CoDeR® and F.I.R.S.T™ platforms.
  • Sharing of technology platforms, knowledge, and expertise.
  • Two clinical trial collaboration and supply agreements with Merck, to evaluate the combination of BI-1206 and Keytruda® as well as BI-1808 and Keytruda®
  • Antibody discovery partnerships
  • Research collaborations